Rezera Inc.

Life Sciences

Boston Biotech Rezera Says Its Pill Boosts Semaglutide's Anti-Inflammatory Effect

Rezera reported positive Phase 2 results on October 7, 2026 for ruvonoflast combined with semaglutide in 82 adults with obesity.